Taiwan to study use of MAO-AI to treat glioma
MAO-AI refers to monoamine oxidase-A inhibitor. Glioma is a primary brain tumor originating in the glial cells in the brain.
MAO-A inhibitor inhibits the activity of the monoamine oxidase-A enzyme. It is used to treat depression. Monoamine oxidase-A regulates the amount of neurotransmitters by removing norepinephrine, serotonin and dopamine in the central nervous system by deactvating and breaking them down. MAO-A inhibitors (MAO-AI) prevent this action.
Too much monoamine oxidase-A is linked to depression while too little monoamine oxidase-A is linked to anxiety and aggressiveness.
When monoamine oxidase-A is not suppressed, a tumor rich environment arises that will fuel metastasis. This is because the break down of the neurotransmitters leaves a lot of debris which enriches the environment for tumor growth.
An international research team from the Los Angeles Cedars Sinai Samuel Oschin Comprehensive Cancer Institute and the University of Southern California found that suppressing the monoamine oxidase-A enzyme or the use of the monoamine oxidase-A inhibitor drug (MAO-AI) reduced and eliminated prostate tumor growth and metastasis in laboratory mice. This has opened the possibility of using antidepressants against prostate cancer in humans.
Administering the antidepressant MAO-AI drug by targeted drug delivery for targeted cancer therapy can be done using Dye Drug Conjugate technology and Near Infrared Dye MAO-A Inhibitor delivery technology.
Taiwan now plans to use the MAO-AI antidepressant drug in clinical studies to target glioma.